Domestic revenues stood at 38% followed by USA- 26, Europe- 22% and RoW- 14% (export revenues- 62%)
Tier1 and Tier 2 suppliers for FMCG customers like, Adani wilmar, colgate, SH kelkar, comtinenatl tyres, CEAT, mischelinen, jk tyres, indian oil, HPCL etc
Expanded capacity from 6000 MT to 11000 MT for rubber, lubricants and speciality segment
Improvement in margins will begin from Q4FY22 onwards
Current capacity utilisation is at peak of 90% (existing + part of new capacities) for 9MFY22 and continues to operate on optimal levels.
Company is evaluating opportunities for capacity expansion
Unexpected incremental cost of power and raw materials will be passed on in next quarter
3-6 months contract with suppliers for procurement. Also having contracts with customer on quarterly to monthly basis and many other are on spot basis
FY22 revenue guidance of ₹540Cr approx.
Applied for EC and under approval process
Working in 3 segments within lubricants i.e antioxidants, corrosion inhibitors and fixer modifiers of which- lubricant is performing well, fixer modifiers approval period is longer and is
picking up well and corrosion inhibitors will be driven by the demand ramp up of ethanol blended fuel
Specialty segment products finds applications in stabilisers for monomer in acids, epoxy resin and thermoplastics
Competitors
1. Food antioxidants- Camlin fine science, Clean science, Solvay
2. Aroma chemicals- manufacturer from Indonesia because clove oil is grown mainly there
3. Rubber segment- NOCIL, LANXESS and some Chinese players
4. Lubricants- BASF , LANXESS and few competition from china
The greenfield project is under consideration and approvals are expected soon.
Moderate growth for 2022-23 and will be more into rubber, lubricants and specialty segment
Increasing R&D capacity and intend to increase R&D spending from this quarter onwards and will be focused on lubricant and rubber products
Long term debt is ₹40-45 Cr and short term debt is ₹100 Cr. Debt reduction will not be anytime soon as focus on greenfield expansion
No customers contributed more the 5% of revenues
Rubber, specialty and lubricants segment have better margins compared to food and aroma business
• • •
Missing some Tweet in this thread? You can try to
force a refresh
1. Revenues for the quarter stood at ₹2376 Cr, with a robust growth of 100.1% YoY
2. Both the Pharmaceuticals & Specialty Chemicals segment outperformed during the quarter
3. Revenue expansion during the quarter includes cost escalations passed on to the customers due to substantial increase in raw material prices as well as fuel and logistics costs
4. Accrual of termination fees in respect of the long-term contract of ₹631 crores resulting in higher revenues. As a result, EBITDA includes ₹611 Crs during the quarter.
1. Revenues from operations stood at Rs. 396.6 crore in Q3FY22 as against Rs. 375.4 crore in Q3FY21, higher by 5.6%
2. EBITDA margins remained stable on a sequential basis at 15.8% translating to EBITDA of 63.8 crore
3. Gross margins in 9M FY22 stood at 41.4%
4. Q3 FY22 revenues growth was driven on the back of rebound in consumer demand led by discretionary items and new client wins.
5. While the domestic core fragrance segment delivered healthy performance, sales in Southeast Asia region continued to be affected by the Covid surge and is yet to recover
1. Revenues for the quarter stood at ₹6002 Cr (1% decline YoY).
2. EBITDA was at ₹1016 Cr (20% decline YoY) for the quarter. EBITDA margins for the quarter were 16.9%. PAT stood at ₹604.3 Cr (80% decline YoY).
3. Revenue from formulations was ₹4992 Cr (12% decline YoY).
4. Formulations contributed about 83% of total revenues. Revenue from the API business stood at ₹1010 Cr (48% growth YoY) and contributed about 17% of revenues.
1. Revenues are flat and profitability is down because of the high base effect.
2. Q3 and Q4 of FY21 were phenomenal quarters for the company because there was a major poultry disease outbreak which led to increased demand for vaccines.
3. They also have additional income every year from licensing fees which is not there in Q3 FY22.
4. They have been working on 3 vaccines - classical swine fever, lumpy skin disease and sheep pox vaccine. All these vaccines are in the final stages of quality testing and regulatory approval and they hope to launch them in Q1 FY23.